New cell shot aims to tame stubborn nerve attacks
NCT ID NCT07265206
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This early-phase trial tests a new cell treatment (HY001N) for people with autoimmune neurological diseases that have not responded to standard therapies. The study will enroll 15 adults to check if the treatment is safe and shows any signs of helping control the disease. The goal is to reduce nerve damage and relapses, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.